These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16302161)

  • 1. Fibrin D-dimer and cardiovascular risk.
    Lowe GD
    Semin Vasc Med; 2005 Nov; 5(4):387-98. PubMed ID: 16302161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease.
    Lowe GD; Rumley A; McMahon AD; Ford I; O'Reilly DS; Packard CJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1529-34. PubMed ID: 15205218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive value of coagulative molecular markers for thromboembolism in patients with nonvalvular atrial fibrillation: prospective five-year follow-up study].
    Enta K; Iwade K; Aosaki M; Uchida T; Kasanuki H
    J Cardiol; 2004 Dec; 44(6):223-32. PubMed ID: 15638220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis.
    Kirmizis D; Tsiandoulas A; Pangalou M; Koutoupa E; Rozi P; Protopappa M; Barboutis K
    Med Sci Monit; 2006 Feb; 12(2):CR55-62. PubMed ID: 16449948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation, calibration, and specificity of quantitative D-dimer assays.
    Dempfle CE
    Semin Vasc Med; 2005 Nov; 5(4):315-20. PubMed ID: 16302152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitral regurgitation reduces systemic coagulation activity in rheumatic heart disease: using fibrin D-dimer as a biomarker of thrombogenesis.
    Tay KH; Khoo CW; Lip GY
    J Heart Valve Dis; 2009 May; 18(3):276-7. PubMed ID: 19557982
    [No Abstract]   [Full Text] [Related]  

  • 7. Mitral regurgitation reduces systemic coagulation activity in patients with rheumatic heart disease.
    Cevik C; Otahbachi M; Nugent K; Ozkan M
    J Heart Valve Dis; 2009 May; 18(3):278-83. PubMed ID: 19557983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of rapid D-dimer measurement for screening of acute cardiovascular disease in the emergency setting.
    Tokita Y; Kusama Y; Kodani E; Tadera T; Nakagomi A; Atarashi H; Mizuno K
    J Cardiol; 2009 Jun; 53(3):334-40. PubMed ID: 19477373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The harmonization of quantitative test results of different D-dimer methods.
    Meijer P; Kluft C
    Semin Vasc Med; 2005 Nov; 5(4):321-7. PubMed ID: 16302153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study.
    Legnani C; Palareti G; Cosmi B; Cini M; Tosetto A; Tripodi A;
    Haematologica; 2008 Jun; 93(6):900-7. PubMed ID: 18443269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in plasma coagulation markers with prophylactic treatment of low molecular weight heparin after cesarean section.
    Hirota Y; Sakai M; Nakabayashi M
    Semin Thromb Hemost; 2005 Jun; 31(3):253-60. PubMed ID: 16052393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coagulation activation is associated with interleukin-6 plasma levels in patients with mechanical prosthetic heart valves.
    Liebe V; Kaden JJ; Isaaci S; Brueckmanni M; Hoffmann U; Bertsch T; Borggrefe M; Dempfle CE
    In Vivo; 2006; 20(3):427-30. PubMed ID: 16724683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study.
    Morange PE; Bickel C; Nicaud V; Schnabel R; Rupprecht HJ; Peetz D; Lackner KJ; Cambien F; Blankenberg S; Tiret L;
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2793-9. PubMed ID: 17023678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reply to Proper observation of patient related factors is an important determinant in the utility of the D-dimer test for exclusion of venous thromboembolism in the ED.
    Ray P
    Am J Emerg Med; 2007 May; 25(4):485-6. PubMed ID: 17499677
    [No Abstract]   [Full Text] [Related]  

  • 15. [Elevated D-dimer in patients with cardiovascular diseases free from thromboembolic complications: what is it associated with and what has to be done?].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV
    Angiol Sosud Khir; 2010; 16(4):34-41. PubMed ID: 21389943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-dimer testing to determine the duration of anticoagulant therapy.
    Palareti G; Cosmi B; Legnani C
    Curr Opin Pulm Med; 2007 Sep; 13(5):393-7. PubMed ID: 17940483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrinogen and cardiovascular disorders.
    Lip GY
    QJM; 1995 Mar; 88(3):155-65. PubMed ID: 7767665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrin D-dimer testing for venous and arterial thrombotic disease.
    Michiels JJ; Palareti G; de Moerloose P
    Semin Vasc Med; 2005 Nov; 5(4):311-4. PubMed ID: 16302151
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of D-dimer testing in patients with suspected venous thromboembolism.
    Prisco D; Grifoni E
    Semin Thromb Hemost; 2009 Feb; 35(1):50-9. PubMed ID: 19308893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma D-dimer concentration in patients with systemic sclerosis.
    Marie I; Borg JY; Hellot MF; Levesque H
    Br J Dermatol; 2008 Feb; 158(2):392-5. PubMed ID: 18028493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.